<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HEMIN</span><br/>(hee'min)<br/><span class="topboxtradename">Panhematin<br/></span><b>Classifications:</b> <span class="classification">blood formers and coagulants</span>; <span class="classification">enzyme inhibitor</span>; <span class="classification">blood derivative</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>7 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Sterile, nonpyrogenic ferric iron complex of protoporphyrin IX; derived from processed red blood cells.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Represses synthesis of porphyrin in liver or bone marrow by blocking production of delta-aminolevulinic acid (ALA) synthetase,
         an essential enzyme in the porphyrin-heme biosynthetic pathway.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Recurrent attacks of acute intermittent porphyria (AIP) only after an appropriate period of alternate therapy has been tried
         (i.e., glucose 400 g/d for 12 d).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to hemin; porphyria cutanea tarda.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Safe use during pregnancy (category C), lactation, or in children is not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Intermittent Porphyria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 14 mg/kg/d administered over 1015 min for 314 d, do not repeat dose earlier than q12h (max: 6 mg/kg in 24
               h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Administer via a large arm vein or central venous catheter to reduce risk of phlebitis. Terminal filtration through a sterile
                     0.45 micron or smaller filter is recommended.
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Reconstitute immediately before use by aseptically adding 43 mL sterile water for injection to vial to yield 7 mg/mL. Shake well for 23 min to dissolve all particles. Discard unused portions. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give a single dose over 1015 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Freeze and store lyophilized powder until time of use.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Phlebitis</span> (when administered into small veins). <span class="typehead">Hematologic:</span> Decreased Hct, anticoagulant effect (prolonged PT, thromboplastin time, thrombocytopenia, hypofibrinogenemia). <span class="typehead">Urogenital:</span> Reversible renal shutdown (with excessive doses). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Potentiates anticoagulant effects of <span class="classification">anticoagulants</span>; <span class="classification">barbiturates</span>, <span class="classification">estrogens</span>, <span class="classification">corticosteroids</span> may antagonize hemin effect. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> Can be detected in plasma up to 5 d. <span class="typehead">Elimination:</span> Excess amounts eliminated in bile and urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor IV site for signs and symptoms of thrombophlebitis (see Appendix F).</li>
<li>Monitor throughout therapy (decrease in these values indicates favorable clinical response): ALA, UPG (uroporphyrinogen),
            PBG (porphobilinogen or coproporphyrin).
         </li>
<li>Monitor clinical effect of drug therapy by checking patient's symptoms and complaints associated with acute porphyria, which
            may include depression, insomnia, anxiety, disorientation, hallucinations, psychoses; dark urine, nausea, vomiting, abdominal
            pain, low back and leg pain, pareses (neuropathy), seizures.
         </li>
<li>Monitor I&amp;O and promptly report the onset of oliguria or anuria.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of bruising, hematuria, tarry black stools, and nosebleeds.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>